Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE).

Full DD Report for ZYNE

You must become a subscriber to view this report.


Recent News from (NASDAQ: ZYNE)

Weekly Cannabis Report: Aurora/MedReleaf, Canopy, Maricann
Welcome to our Weekly Cannabis Report, a reliable source for cannabis investors to receive the latest developments and analysis. Weekly Note to Readers The cannabis sector saw its biggest acquisition to-date when Aurora (ACBFF) finally announced the acquisition of MedReleaf (MEDFF) for a h...
Source: SeekingAlpha
Date: May, 15 2018 10:20
Zynerba: Transdermal Cannabinoids Have Significant Potential
Understanding Cannabadiol ("CBD") vs. Tetrahydrocannabinol ("THC") Many people have been conditioned to have reflex reactions (both positive and negative) to anything that relates to cannabis/marijuana. In fact, I'm sure at least a few readers of this article will have opened it solely be...
Source: SeekingAlpha
Date: May, 15 2018 05:55
Weekly Cannabis Report: MedReleaf Sell, TGOD IPO, Loblaw Wins
Welcome to our Weekly Cannabis Report, a reliable source for cannabis investors to receive the latest developments and analysis. Weekly Note to Readers There are three things that cannabis investors need to know from last week. Fourth-largest Canadian cannabis company MedReleaf is reported...
Source: SeekingAlpha
Date: May, 08 2018 15:20
Zynerba Pharmaceuticals Reports First Quarter 2018 Financial Results and Operational Highlights
DEVON, Pa., May 08, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and nea...
Source: GlobeNewswire
Date: May, 08 2018 07:30
Weekly Cannabis Report: U.S. Federal Legalization And The Green Organic Dutchman's IPO
Welcome to our Weekly Cannabis Report, a reliable source for cannabis investors to receive the latest developments and analysis. Weekly Note to Readers This past week was relatively quiet for the cannabis world and we are seeing some weakness across the sector as share prices drifted lower...
Source: SeekingAlpha
Date: May, 01 2018 17:10
Your Daily Pharma Scoop: Takeda Acquisitions, Concert Trial Update, Sangamo Offering
Analysis focus: Takeda As I was telling Brian Bain of DIY Investing yesterday in an interview (a part of their DIY Summit - see here ), there’s a lot of talk going on about repatriated American tax dollars set to start a boom in M&A. However, quietly in the background, these ...
Source: SeekingAlpha
Date: April, 26 2018 08:00
Zynerba Announces Data From Study in Patients With Focal Seizures
LOS ANGELES, April 25, 2018 ( GLOBE NEWSWIRE ) -- Zynerba Pharmaceuticals, Inc. ( NASDAQ:ZYNE ), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and ...
Source: Daily Marijuana Observer
Date: April, 25 2018 09:40
Zynerba's ZYN002 show positive effect in focal seizure extension study
Results from an open-label extension study, STAR 2, assessing Zynerba Pharmaceuticals' (NASDAQ: ZYNE ) lead candidate ZYN002 in adult patients with focal seizures showed a treatment effect. The data are being presented at the American Academy of Neurology Annual Meeting in Los Angeles. ...
Source: SeekingAlpha
Date: April, 25 2018 07:43
Zynerba Pharmaceuticals Announces Twelve Month ZYN002 Data from STAR 2 Study in Patients with Focal Seizures at the 2018 Annual Meeting of the American Academy of Neurology (AAN)
Continued Improvement in Seizure Control Seen in Adult Refractory Focal Seizure Patients Receiving ZYN002 through 12 Months of Open Label Exposure LOS ANGELES, April 25, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage speci...
Source: GlobeNewswire
Date: April, 25 2018 07:00
Weekly Cannabis Report: We Are Entering Cannabis 2.0
Welcome to our Weekly Cannabis Report, a reliable source for cannabis investors to receive the latest developments and analysis. Foreword For the past month, we have taken the time to develop one of the most comprehensive coverages on the cannabis sector for readers. As we announced in t...
Source: SeekingAlpha
Date: April, 24 2018 11:29

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-179.479.819.979.35248,140
2017-03-1020.5820.2720.6720.2445,112
2017-03-0920.8220.3821.172420.16226,516
2017-03-0820.0721.1121.6020.07276,003
2017-03-0720.5120.0920.639919.69381,902

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1740,74459,52268.4520Short
2018-08-1636,28560,10360.3714Short
2018-08-1534,62055,71862.1343Short
2018-08-1432,39961,21452.9274Short
2018-08-1333,44576,64543.6362Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ZYNE.


About Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)

Logo for Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $125,171,473 - 05/11/2018
  • Issue and Outstanding: 13,561,373 - 03/08/2018

 


Recent Filings from (NASDAQ: ZYNE)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 25 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 23 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 12 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 12 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 12 2018

 

 


Daily Technical Chart for (NASDAQ: ZYNE)

Daily Technical Chart for (NASDAQ: ZYNE)


Stay tuned for daily updates and more on (NASDAQ: ZYNE)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ZYNE)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ZYNE is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ZYNE and does not buy, sell, or trade any shares of ZYNE. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/